First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices

Liu, Stephen V.; Rai, Pragya; Wang, Dong; Hu, Xiaohan; Schwarzenberger, Paul

doi:10.1016/j.jtocrr.2022.100444

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another study by Liu et al. analysed a group of 364 patients in good performance status (ECOG 0-1) diagnosed with squamous-cell lung cancer ( 21 ). Of these, 94 patients had expression of PD-L1 <1% (26%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice

Knetki-Wróblewska,

Dziadziuszko,

Jankowski

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

IntroductionPembrolizumab combined with chemotherapy has become the standard of care for patients with non-small-cell lung cancer (NSCLC) and the expression of programmed death ligand 1 (PD-L1) in <50% of tumour cells (TC).MethodsWe evaluated the efficacy of the treatment in real-world practice, paying attention to the predictive factors, with a special focus on low level of PD-L1 expression. This study is a multicenter retrospective analysis of patients with stage IV NSCLC.ResultsA group of 339 consecutive patients was analysed, among them 51% patients with low PD-L1 expression. In the overall population, the ORR was 40.6%, median PFS and OS were 13 months (95% CI 11.4-15) and 16.8 months (95% CI 13.3-20.3), respectively. In multivariate analysis for the entire study population, performance status – ECOG 1 vs. 0 (HR 2.2, 95%CI 1.1-4.6; p=0.02), neutrophil to lymphocyte ratio (NLR)>3 (HR 2.3, 95%CI 1.3-4.2; p=0.04), presence of liver (HR 2.0, 95%CI 1-3.7; p=0. 03) and bone metastases (HR 1.3, 95%CI 1-3; p=0.04), weight loss (HR 1.8, 95%CI 1.1-2.8; p=0.01) and sum of measurable lesions diameters >110 mm (HR 1.7, 95%CI 1-2.9, p=0.049) had a negative impact on OS.ConclusionsIn the real world, patients can clinically benefit from immunochemotherapy, regardless of the expression of PD-L1 and the histological type. Other clinicopathological factors such as performance status, extent, and location of secondary lesions have prognostic significance.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The median OS was 16.2 months (95% CI: 10.3-20.6) for PD-L1 ≥ 1% and 17.2 months (95% CI: 10.8-20.6) for PD-L1 < 1%. The percentage of patients who remained in follow-up after one year of treatment was similar in both subgroups (approximately 55%) ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice

Knetki-Wróblewska,

Dziadziuszko,

Jankowski

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer

Zhang,

Yin,

Zhang

et al. 2024

Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

Immune Checkpoint Inhibitors in first versus second line of metastatic non-small cell lung cancer: Real-World Overall Survival

Yudin,

Laktionov,

Breder

et al. 2024

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. Although immuneand targeted therapy have become successful in recent years, platinum-based chemotherapy continues to have a place in the up-front treatment for metastatic non-small cell lung cancer (NSCLC).Aim. Tо evaluate the overall survival (OS) of patients with metastatic NSCLC who were treated with immune checkpoint inhibitors either as first-line or second-line treatment in clinical practice in Russia.Materials and methods. Using real-world database, we retrospectively selected 232 patients with metastatic NSCLC without driving mutations. Of these patients, 82 received chemoimmunotherapy as the initial treatment (group 1) and 150 patients were treated with platinum–based chemotherapy followed by immunotherapy as the second line (group 2). Multivariate subgroup analyses were performed. The median time from the start of treatment to data cut off was 38.4 months.Results. The median OS was the same in the first and second group, 21.0 months (14.4–27.6; 95% CI) and 22.4 months (17.6–27.19; 95% CI); estimated 3-year OS was 40% and 36.6%, respectively. The hazard ratio (HR) for patients in the immunochemotherapy group was 1.02 (0.72–1.44; 95% CI) compared with patients who received second-line immunotherapy. In multivariate analysis, non-compliance with basic inclusion criteria in clinical trials (ECOG 2–3, serious intercurrent illness, active infection, chronic infection, corticosteroids need) (HR = 1.71 (1.21–2.4; 95% CI), the liver metastasis (HR = 1.76 (1.09–2.84; 95% CI) and gender (male vs. female HR = 1.68 (1.04–2.71; 95% DI) were significantly associated with the shorter OS.Conclusions. The overall survival in patients who received immunotherapy in the second line of treatment did not differ from the results of treatment for the patients after immuno-chemotherapy in the first line. The crucial is the receiving of immunotherapy regardless of the line. Failure to meet the criteria of inclusion in clinical trials significantly worsens the long-term outcomes.

show abstract

First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices

Cited by 4 publications

References 27 publications

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice

Pembrolizumab-combination therapy for NSCLC- effectiveness and predictive factors in real-world practice

Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer

Immune Checkpoint Inhibitors in first versus second line of metastatic non-small cell lung cancer: Real-World Overall Survival

Contact Info

Product

Resources

About